Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of ($0.78), $0.03 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $17.9 million versus the consensus estimate of $17.16 million.

Tandem Diabetes sees FY2015 revenue of $70-75 million, versus the consensus of $75.26 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.